Monitor upcoming initiation of patient dosing in the DReAMzz study as a near-term catalyst; the AASM partnership enhances scientific credibility but does not alter near-term financial or clinical trajectory.
Price Chart
Executive Summary
Incannex Healthcare announced a partnership with the AASM Foundation to sponsor a grant for junior researchers focused on sleep apnea, reinforcing its commitment to the sleep medicine community as it advances its lead candidate IHL-42X for obstructive sleep apnea. The partnership includes promotional collaboration but does not involve direct financial terms or material commercial impact.
Key Facts
- Incannex entered a partnership with the AASM Foundation to sponsor a Focused Projects Grant for junior investigators researching sleep apnea.
- The grant will be awarded in 2026 and will support independent research in diagnosis, management, and treatment of sleep apnea.
- IHL-42X, Incannex’s lead candidate for OSA, has completed a positive Phase 2 trial and received FDA Fast Track designation.
- The DReAMzz Phase 2 dose-optimization study is expected to begin patient dosing soon, ahead of a planned Phase 3 trial.
- No financial terms of the sponsorship were disclosed.
Financial Impact
Minimal to no material financial impact; no dollar amount disclosed for sponsorship
Risk Factors
- Lack of disclosed funding amount limits assessment of financial exposure.
- Clinical development risk remains high for IHL-42X despite positive Phase 2 data and Fast Track status.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262131 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.61 (−19.20%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.61 (−30.40%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.61 (−18.44%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.61 (−17.41%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.61 (−17.41%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.61 (−33.25%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.61 (−33.25%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.61 (−28.88%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.61 (−32.73%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.61 (−32.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers